Literature DB >> 16702386

Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.

Christopher A Haiman1, Daniel O Stram, Iona Cheng, Elena E Giorgi, Loreall Pooler, Kathryn Penney, Loïc Le Marchand, Brian E Henderson, Matthew L Freedman.   

Abstract

PTEN frequently shows loss of heterozygosity in breast and prostate cancers, and mutations in this gene are responsible for Cowden disease, a rare Mendelian syndrome that includes breast cancer as part of its phenotype. Thus, PTEN serves as a candidate susceptibility gene for both breast and prostate cancer risk. Whether common inherited variation (either coding or noncoding) at the PTEN locus contribute to nonfamilial, sporadic breast and prostate cancer risk is not known. In this study, we employed a linkage disequilibrium-based approach to test for association between common genetic variation at the PTEN locus and breast and prostate cancer risk in African-American, Native Hawaiian, Japanese, Latina, and White men and women in the Multiethnic Cohort Study. We genotyped 17 common single nucleotide polymorphisms (SNP; >/=5% frequency in at least one ethnic group) spanning the PTEN gene to define the common alleles in these populations. These SNPs were in strong linkage disequilibrium, indicating that our survey captured most of the common sequence variation across this locus. Eight tagging SNPs were selected to predict the common PTEN haplotypes (>/=0.05 frequency) in these populations (two additional tagging SNPs were required for African Americans). These SNPs were evaluated in a breast cancer case-control study (cases, n = 1,615; controls, n = 1,962) and prostate cancer case-control study (cases, n = 2,320; controls, n = 2,290) nested within the Multiethnic Cohort Study. Multiple testing was explicitly accounted for by applying a permutation-based framework. We found no strong association with any common haplotype in relation to breast or prostate cancer risk. In summary, our results show that common variants in PTEN do not substantially influence risk of these two common cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702386     DOI: 10.1158/1055-9965.EPI-05-0896

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  16 in total

1.  Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility.

Authors:  Chunmei C Xie; Lingyi Lu; Jielin Sun; S Lilly Zheng; William B Isaacs; Henrik Gronberg; Jianfeng Xu
Journal:  J Hum Genet       Date:  2011-06-02       Impact factor: 3.172

2.  No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer.

Authors:  Lynette S Phillips; Cheryl L Thompson; Alona Merkulova; Sarah J Plummer; Thomas C Tucker; Graham Casey; Li Li
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

3.  Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.

Authors:  Marcus G Pezzolesi; Yan Li; Xiao-Ping Zhou; Robert Pilarski; Lei Shen; Charis Eng
Journal:  Am J Hum Genet       Date:  2006-09-29       Impact factor: 11.025

4.  Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.

Authors:  Stella Koutros; Fredrick R Schumacher; Richard B Hayes; Jing Ma; Wen-Yi Huang; Demetrius Albanes; Federico Canzian; Stephen J Chanock; E David Crawford; W Ryan Diver; Heather Spencer Feigelson; Edward Giovanucci; Christopher A Haiman; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Peter Kraft; Loïc Le Marchand; Elio Riboli; Afshan Siddiq; Mier J Stampfer; Daniel O Stram; Gilles Thomas; Ruth C Travis; Michael J Thun; Meredith Yeager; Sonja I Berndt
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

Review 5.  Cowden syndrome: a critical review of the clinical literature.

Authors:  Robert Pilarski
Journal:  J Genet Couns       Date:  2008-10-30       Impact factor: 2.537

6.  Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population.

Authors:  Martha L Slattery; Esther M John; Gabriela Torres-Mejia; Abbie Lundgreen; Jennifer S Herrick; Kathy B Baumgartner; Lisa M Hines; Mariana C Stern; Roger K Wolff
Journal:  Carcinogenesis       Date:  2012-05-04       Impact factor: 4.944

7.  Expression of FAK and PTEN in bronchioloalveolar carcinoma and lung adenocarcinoma.

Authors:  Changli Wang; Ran Yang; Dongsheng Yue; Zhenfa Zhang
Journal:  Lung       Date:  2009-02-26       Impact factor: 2.584

8.  Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.

Authors:  Frédéric Guénard; Yvan Labrie; Geneviève Ouellette; Charles Joly Beauparlant; Paul Bessette; Jocelyne Chiquette; Rachel Laframboise; Jean Lépine; Bernard Lespérance; Roxane Pichette; Marie Plante; Francine Durocher
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375

9.  Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.

Authors:  James V Lacey; Hannah Yang; Mia M Gaudet; Alison Dunning; Jolanta Lissowska; Mark E Sherman; Beata Peplonska; Louise A Brinton; Catherine S Healey; Shahana Ahmed; Paul Pharoah; Douglas Easton; Stephen Chanock; Montserrat Garcia-Closas
Journal:  Gynecol Oncol       Date:  2010-11-20       Impact factor: 5.482

10.  Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.

Authors:  Jiawei Chen; Pengfei Shao; Qiang Cao; Pu Li; Jie Li; Hongzhou Cai; Jian Zhu; Meilin Wang; Zhengdong Zhang; Chao Qin; Changjun Yin
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.